CD274 and neoplasm: Consistent with the hypothesis that AZD1390 enhances the radiation-induced antitumoral immune response to sensitize to immunotherapy, the triplet combination of AZD1390, radiation, and anti–PD-L1 significantly inhibited tumor growth and delayed tumor volume doubling with minimal toxicity during therapy, as assessed by weight loss (Figure 3, B and C, and Supplemental Figure 3, A and B).